Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 927 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vascular Disease Risk Clear all
Completed No phase listed Observational Accepts healthy volunteers

Socioeconomic Status, Psychosocial Factors, and CVD Risk in Mexican-American Women

NCT00387166
View directory record Official record
Conditions
Hypertension, Cardiovascular Disease, Metabolic Disorders
Interventions
Not listed
Lead sponsor
San Diego State University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Muscadine Grape Seed Supplementation and Vascular Function

NCT01011517
View directory record Official record
Conditions
Dietary Supplements
Interventions
Muscadine grape seed supplement
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 14, 2026, 8:20 AM EDT
Recruiting Phase 2 Interventional

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

NCT06100237
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Teclistamab, Talquetamab, Daratumumab SC
Drug
Lead sponsor
Carl Ola Landgren, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

NCT00064337
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
35
States / cities
Little Rock, Arkansas • Sacramento, California • Boise, Idaho + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 14, 2026, 8:20 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib in High-Risk Vascular Disease

NCT01687998
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Evacetrapib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,092 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 173 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 14, 2026, 8:20 AM EDT
Recruiting Phase 2 Interventional

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

NCT06948084
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, FDG-Positron Emission Tomography, Pomalidomide, Teclistamab
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
23
States / cities
Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 14, 2026, 8:20 AM EDT
Recruiting Not applicable Interventional

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

NCT07296744
View directory record Official record
Conditions
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention, Interventional Cardiology, Mechanical Circulatory Support
Interventions
The Supira System, Impella
Device
Lead sponsor
Supira Medical
Industry
Eligibility
18 Years to 90 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Loma Linda, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 14, 2026, 8:20 AM EDT
Terminated Not applicable Interventional

Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)

NCT00477477
View directory record Official record
Conditions
Childhood Obesity, Dyslipidemia, Insulin Resistance, Hypertension
Interventions
Diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 14, 2026, 8:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cardiovascular Disease Risk Factors in Chinese American Immigrants

NCT00362128
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
2,072 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 3 Interventional

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
View directory record Official record
Conditions
Coronary Atherosclerosis
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Not applicable Interventional

Evaluation of a Navigator-Nurse Care Team on the Management of High Blood Pressure and Cardiovascular Disease Risk

NCT00523536
View directory record Official record
Conditions
Hypertension
Interventions
Patient Navigator - Nurse Team Intervention
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
21 Years to 74 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2013 · Synced Oct 14, 2026, 8:20 AM EDT
Terminated Phase 3 Interventional Results available

Pravastatin to Prevent Preeclampsia

NCT03944512
View directory record Official record
Conditions
Preeclampsia, Obstetric Labor Complications, Hypertension in Pregnancy
Interventions
Pravastatin, Placebo
Drug · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
16 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Birmingham, Alabama • Chicago, Illinois • New York, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 14, 2026, 8:20 AM EDT
Not yet recruiting Phase 2 Interventional

A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease

NCT07839936
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease, Hypercholesterolemia
Interventions
VERVE-102, Placebo
Drug
Lead sponsor
Verve Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
DeSoto, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Walnut Intake on Vascular Function and Metabolism

NCT03900403
View directory record Official record
Conditions
Overweight and Obesity, Endothelial Dysfunction, Cardiovascular Risk Factor
Interventions
Walnut Intake
Other
Lead sponsor
University of California, Davis
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

NCT01131169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
busulfan, melphalan and fludarabine
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 72 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

NCT05563246
View directory record Official record
Conditions
Lipoprotein Disorder
Interventions
LY3473329, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Baltimore, Maryland • Dorchester, Massachusetts • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 4 Interventional Results available

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

NCT02584660
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban, Standard-of-care
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 2 Interventional Results available

Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)

NCT01625845
View directory record Official record
Conditions
Major Depressive Disorder, Depression, Depressive Symptoms, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Heart Disease
Interventions
Pentoxifylline, Placebo, Standard Treatment
Drug · Other · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 14, 2026, 8:20 AM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries

NCT02339818
View directory record Official record
Conditions
Stroke, Systemic Embolism, VTEt and VTEp
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 1 Interventional

Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

NCT01707394
View directory record Official record
Conditions
Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Day to 18 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
18
States / cities
Little Rock, Arkansas • Orange, California • Hartford, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 14, 2026, 8:20 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 14, 2026, 8:20 AM EDT
Active, not recruiting Phase 3 Interventional

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

NCT06383390
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
204
States / cities
Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 14, 2026, 8:20 AM EDT
Completed Phase 1Phase 2 Interventional

Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia

NCT00616980
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Critical Limb Ischemia
Interventions
CD34-positive cells, Saline and 5% autologous plasma
Biological
Lead sponsor
Losordo, Douglas, M.D.
Individual
Eligibility
21 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Gainsville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 14, 2026, 8:20 AM EDT